steroid-refractory acute graft versus host disease
Mesoblast CEO Slashes Salary by 30% to Fund Cell Therapy Trial
Anika Sharma
In a bold move reflecting commitment to the company’s mission, Mesoblast’s CEO has chosen to lead by example by implementing ...
